The purpose of this study is to learn how the body processes the study medicine PF-07104091. The study is seeking participants who are: \- Healthy male aged 18 to 65 years of age Participants in the study will receive 14C-labeled PF-07104091 by mouth after a meal. After 14 days, the participants will receive PF-07104091 by mouth (after a meal) followed by IV fusion (given directly into a vein) of microdose \[14C\]PF-07104091. The study will help understand how the body processes study medicine PF-07104091 and how the medicine is changed and removed from the body after you take it. This study will also help to understand how much PF-07104901 is taken up into the blood. Participants will remain in the study clinic for a maximum of 23 days and will have one follow-up contact.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Percentage of Total Radiocarbon (14c) excreted in urine
Timeframe: From Predose up to 14 days post dose of period 1 and 2
Percentage of Total Radiocarbon (14c) excreted in feces
Timeframe: From Predose up to 14 days post dose of period 1 (and if applicable for Period 2)
Percentage of Total Radiocarbon (14c) excreted in vomitus (if applicable)
Timeframe: From Predose up to 14 days post dose of period 1 only
Cumulative Percent Recovery of Total Radiocarbon (14C)
Timeframe: From Predose up to 14 days post dose of period 1 only
Percentage of Metabolite Detected in Plasma After Oral Administration of PF-07104091
Timeframe: From Predose to 14 days post dose of period 1
Percentage of Metabolite Detected in Urine After Oral Administration of PF-07104091
Timeframe: From Predose to 14 days post dose of period 1
Percentage of Metabolite Detected in Feces After Oral Administration of PF-07104091
Timeframe: From Predose to 14 days post dose of period 1